<DOC>
	<DOC>NCT01575769</DOC>
	<brief_summary>This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment is 104 weeks.</brief_summary>
	<brief_title>An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Patients who completed 104 weeks of study WA19977 with at least a JIA ACR30 clinical response to RoActemra/Actemra and no serious adverse event or adverse event Written informed consent obtained from patient if patient is 18 years of age and older, or if under the age of 18 years from parents or legal guardian Patient did not benefit from RoActemra/Actemra therapy in study WA19977 Treatment with any investigational drug since the last administration of study drug in the core study WA19977 Patients developed any other autoimmune rheumatic disease other than the permitted JIA subsets Any significant medical or surgical condition that would jeopardize patient's safety Current serious uncontrolled concomitant disease or infection</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>